fbpx

WHY IMMUNOTHERAPY TREATMENT?

Immunotherapy is a breakthrough treatment that strengthens the immune system – enabling it to recognize, remember, and fight cancer cells. The treatment, applied through an immune checkpoint blocker, may help slow down or stop the growth of cancer cells in the patient’s body – boosting overall survival and improving the quality of life.

To learn more about immunotherapy and how it may help you or a loved one, talk to a medical oncologist.

Biomarker Testing

Biomarkers are crucial measurable indicators of the presence or severity of a disease and its state. Understanding the presence of biomarkers can help doctors predict the body’s response to certain treatments.

MSI Testing

A specialized type of procedure called microsatellite instability (MSI) testing can provide significant benefits to advanced cancer patients.

BIOMARKER TESTING

What is it? How does it work?

AN IMPORTANT FACTOR OF PERSONALIZED MEDICINE

TARGET FOR IMMUNOTHERAPY

ENSURING MAXIMUM BENEFIT

WHAT IS MSI?

MSI

Microsatellite instability is a genetic marker, which may be found in many types of cancer. It happens when the body stops correcting certain mistakes in cells.

What is MMR?

Mismatch Repair (MMR) is the body’s spellchecker. It finds mistakes in cells and fixes them. But sometimes the MMR can stop working properly.

QUOTES FROM SPECIALISTS

Dr. Cesar Recto II

“With the availability of targeted therapies and new treatment options like immunotherapy, there’s hope to prolong life.”

Dr. Cesar Recto IIMedical Affairs Director, MSD
Professor Morteza Aghmesheh

“The interesting thing about immunotherapy is, when a head and neck cancer patient is responsive to it, he or she will continue to receive the benefits of the treatment. So when you follow these patients for two years, you’ll find that 70 to 80 percent of them remain responsive to the treatment.”

Professor Morteza AghmeshehMedical Oncologist and Cancer Researcher, Wollongong Hospital in Australia
Dr. Daniel Chan

“There was a lot of skepticism in the medical community that something as gentle as immunotherapy could work for something as aggressive as cancer. But from recent clinical trials we now know that it could be effective in the right circumstances.”

Dr. Daniel ChanMedical Oncologist, Mount Elizabeth Medical Centre, Singapore
Oscar Chan

“In the past, majority of lung cancer patients can only live one year. The median survival is only around a year to 17 months. But with the introduction of immunotherapy, the patient can live longer; the response rate is high and is more consistent.”

Oscar ChanLung, Head and Neck Cancer Specialist, Hong Kong Integrated Oncology Centre